ABSTRACT-We investigated the effects of the newly synthesized proton pump inhibitor TY-1 1345, (±)-2 [(4-methoxy-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl)sulfinyl]-1H-benzimidazole sodium salt, on gastric mucosal proton pump (H+/K+-ATPase) activity, gastric acid secretion and gastro-duodenal lesions in experimental animals. TY-11345 potently inhibited H+/K+-ATPase activity in isolated rabbit gastric mu cosal microsomes; and the inhibitory effect was enhanced under weak acid conditions, the IC50 (concentra tions that inhibit the enzyme activity by 50%) being 5.8 , tM and 9.9 pM at pH 6.0 and pH 7.4, respectively. In Ghosh & Schild rats, intravenous injection of TY-11345 significantly inhibited gastric acid secretion stimulated by tetragastrin; the effect of TY-11345 was twice as potent as that of omeprazole. In pylorus ligated rats, TY-11345 inhibited basal gastric acid secretion by both the intraduodenal and oral routes, with ED50 values of 1.2 and 4.0 mg/kg, respectively. These effects were 9 and 5 times more potent than those of omeprazole, respectively. Moreover, the antisecretory effect of TY-1 1345 persisted for more than 24 hr in pylorus ligated rats. In experimental ulcer models, TY-11345 prevented the formation of water-immersion stress, ethanol or indomethacin-induced gastric lesions and mepirizole-induced duodenal lesions in rats. The antiulcer effects of TY-11345 were 3 to 15 times more potent than those of omeprazole. These results suggest that TY-11345 has potent antisecretory and antiulcer effects which are exerted by suppression of H+/K+-ATPase activity in gastric parietal cells, so that TY-11345 should be useful for the clinical treatment of peptic ulcer diseases.
Gastric acid has been demonstrated to be a major fac tor in peptic ulcer diseases. In 1967, Forte et al. demon strated the existence of a K+-stimulated ATPase in gastric mucosal microsomes prepared from rabbits during their investigations on the production and secretory mecha nisms of gastric acid (1) . Lee et al. reported the mecha nisms of the ATPase responsible for generation of the hydrogen ion gradient at the luminal surface of gastric parietal cells (2) . These observations indicated that the enzyme involved in the final step of acid secretion is the H+/K+-ATPase "proton pump". In 1981, Fellenius et al. demonstrated that substituted benzimidazole inhibited the H+/K+-ATPase and sup pressed gastric acid secretion (3) . This work led to the discovery of the proton pump inhibitor omeprazole.
Omeprazole has a pyridine ring, CH2SO and a benzimida zole ring as fundamental structural elements. This com pound is activated under acid conditions to form a sul fenamide which modifies the SH substrate of H+/K+ ATPase (4, 5) . TY-11345, (±)-2-[(4-methoxy-6,7,8,9-tetrahydro-5H cyclohepta [b] pyridin-9-yl)sulfinyl]-1H-benzimidazole so dium salt, is a new benzimidazole derivative with a cyclo heptenopyridine ring, and our previous study has rev ealed that TY-11345 has a potent inhibitory effect on H+/K+-ATPase activity, and the effect is enhanced by decreasing the pH of the medium (6) . Our present study shows the antisecretory and antiulcer properties of TY 11345 in experimental animals and compares these results with the properties of omeprazole. 
MATERIALS AND METHODS
Test compounds TY-11345 ( Fig. 1 ) and omeprazole were synthesized by Toa Eiyo. For the in vitro study, these compounds were dissolved in dimethyl sulfoxide (DMSO) and then diluted with 10 mM imidazole buffer (pH 6.0 or 7.4), with the final concentration of DMSO being less than 1%. For the in vivo studies, these compounds were dissolved in poly ethylene glycol 400 (PEG) and then diluted with 0.56 mg/ml NaHCO3 (less than 10% PEG) for intravenous ad ministration or suspended in 0.5% carboxymethyl cellu lose sodium salt (CMC-Na) solution combined with 0.2% NaHCO3 for oral and intraduodenal administration. TY 11345 and omeprazole were administered in a volume of 2 ml/kg body weight in the in vivo studies.
H+/K'-ATPase activity in gastric mucosal microsomes Preparation of rabbit gastric membranes enriched in H+/K+-ATPase:
Gastric H+/K+-ATPase was purified from the parietal cell-rich fraction of the rabbit stomach in accordance with the method of Saccomani et al. (7) . The stomach of Japanese white rabbits (2.5 to 3.5 kg) was dissected out and washed quickly with ice-cold 3 M NaCI. The fundic mucosa was removed from the underlying muscular layer and homogenized in 10 volumes of ice cold Tris-HCI/sucrose buffer (20 mM/250 mM, pH 7.4) by a Teflon-glass homogenizer. The resulting homog enates were centrifuged at 9,000 x g for 10 min. The pellets were suspended in a twofold volume homogenate buffer and centrifuged again under the same conditions. The resulting supernatants of the two centrifugations were combined and recentrifuged at 105,000 x g for 60 min. The microsomal pellets were resuspended in the 250 mM sucrose and layered over 7.5% Ficol (w/w) in 250 mM sucrose. Centrifugation was carried out in an SRP 28A swing rotor (Hitachi, Tokyo) at 25,000 rpm for 4 hr. The light microsomal bands at the interface between the 250 mM sucrose and Ficol were collected. The preparations were stored at 80'C until use. Protein content was meas ured by the commercially available protein assay kit (Bio Rad, Richmond, CA, USA) using bovine serum albumin as the standard.
Assay procedure: Rabbit gastric H+/K+-ATPase was measured as described by Saccomani et al. (7) . Briefly, membrane protein (80 tcg protein) was preincubated for 3 to 30 min at 37 C in an assay medium consisting of 10 mM imidazole buffer (pH 6.0 or 7.4) and various concen trations of TY-11345 or omeprazole (final volume of 0.5 ml). The enzyme reaction was started by adding 0.5 ml of a solution containing 4 mM MgC12, 4 mM ATP, 2 x 10-5 M valinomycin and 80 mM imidazole buffer (pH 7.4), with or without 20 mM KCI. The reaction was stopped after a 15-min incubation at 371C by placing the tubes in ice-slush and adding 1 mM ice-cold 12% trichloroacetic acid. Inorganic phosphate produced from ATP hydrolysis was measured by a commercially available assay reagent for inorganic phosphate (Iatron-Ma701 Pi, latron, Tokyo).
Measurement of gastric acid secretion
Tetragastrin-stimulated secretion (Ghosh & Schild rats): A modified method based on the technique of Ghosh and Schild was utilized (8) . Male Sprague-Dawley rats (213 364 g) were deprived of food but allowed free access to water for 24 hr prior to the experiments. Rats were anesthetized with urethane (1.25 g/kg, i.p.). A poly ethylene tube was inserted into the trachea to facilitate spontaneous breathing. A midline laparotomy was then performed, and the stomach was exteriorized. Through an incision in the forestomach, the gastric contents were gently washed out with saline. A double-lumen cannula (outer: Tygon with a diameter of 7 mm, inner: polyethyl ene with diameter of 2 mm) was inserted into the fore stomach and secured by a ligature at the forestomach. The pylorus was ligated, and saline at room temperature was infused through the inner cannula at a rate of 1.0 ml/min and drained from the outer tube. The gastric secretion was stimulated by a constant infusion of tetragastrin (Mect, Tokyo; 30 pg/kg/hr, i.v.). The gastric effluent was collected at 10-min intervals. The acid output (in microequivalents per min) was determined by titration of the perfusate with 0.01 N NaOH to pH 7.0 with an automatic titrator (AUT-201, Toa Denpa, Tokyo). TY 11345 (0.3, 0.5 and 1.0 mg/kg), omeprazole (0.3, 0.5 and 1.0 mg/kg) or vehicle were administered from the femoral vein after the gastric acid secretion reached a plateau.
Basal secretion (pylorus ligated rats): Male Sprague Dawley rats (232-267 g) were deprived of food but al lowed free access to water for 24 hr prior to the experi ments. While under ether anesthesia, the abdomen was opened and the pylorus ligated. Test compounds or vehi cle were administered intravenously (TY-11345: 0.1, 0.3 and 1.0 mg/kg; omeprazole: 1.0, 3.0 and 10 mg/kg); intra duodenally (TY-11345: 1, 3 and 10 mg/kg; omeprazole: 3, 10 and 30 mg/kg), immediately after the ligation; or oral ly, at 0.5 (3, 10 and 30 mg/kg) or 19 hr (10, 30 and 100 mg/kg) before the ligation. Five hours after the pylorus ligation, the rats were sacrificed. The gastric contents were collected and analyzed for the volume and acidity. The acid concentration in a 1-ml aliquot of the gastric juice was determined by an automatic titrator against 0.1 N NaOH to pH 7.0. The total acid output was calculated as the volume times the acid concentration.
Acute experimental lesions
Water-immersion stress-induced gastric lesions: Male Sprague-Dawley rats (190-273 g) were deprived of food but allowed free access to water for 24 hr prior to the experiments. The rats were placed in a restraint cage, and then immersed vertically to the level of the xiphoid process in a water bath (231C) for 6 hr and sacrificed (9) . The stomach of each rat was removed and inflated by in jecting 8 ml of 1% formalin to fix the inner and outer lay ers of the gastric wall. This formalin treatment was per formed in all of the following experiments. Subsequently, the stomach was incised along the greater curvature and examined for lesions in the glandular portion. Test com pounds (TY-11345: 0.3, 1.0 and 3.0 mg/kg; omeprazole: 3, 10 and 30 mg/kg) or vehicle were administered orally at 30 min before the stress load.
Indomethacin-induced gastric lesions: Male Sprague Dawley rats (178-285 g) were deprived of food but al lowed free access to water for 24 hr prior to the experi ments. Indomethacin, suspended in 0.5% CMC-Na, was orally given in a dose of 10 mg/kg (10) . The rats were sacrificed 6 hr later, and the stomach was examined for lesions in the glandular portion. Test compounds (TY 11345: 0.3, 1.0 and 3.0 mg/kg; omeprazole: 3, 10 and 30 mg/kg) or vehicle were administered orally at 30 min be fore the indomethacin treatment.
Ethanol-induced gastric lesions: Male Sprague-Dawley rats (215 315 g) were deprived of food but allowed free access to water for 24 hr prior to the experiments. The rats were each orally given 1 ml absolute ethanol (11) . The rats were sacrificed at 1 hr after receiving the ethanol, and then the stomach was examined for lesions in the glan dular portion. Test compounds (3, 10 and 30 mg/kg) or vehicle were administered orally at 30 min before the ethanol treatment.
Mepirizole-induced duodenal ulcers: Male Sprague Dawley rats (215 285 g) were used. Mepirizole, suspend ed in 0.5% CMC-Na, was administered orally at 200 mg/kg to rats, which were then deprived of food and water (12) . The rats were sacrificed 24 hr later and exam ined for ulcers in the duodenum. Test compounds (TY 11345: 0.3, 1 and 3 mg/kg x 2; omeprazole: 1, 3 and 10 mg/kg x 2) or vehicle were administered orally twice, at 30 min before and 9 hr after the mepirizole treatment.
Chronic experimental ulcers
Acetic acid-induced gastric ulcers: Male Sprague Dawley rats (192-218 g) were used. Prior to the experi ments, the abdomens of ether anesthetized rats were in cised and the anterior portion of the stomach exposed. Then, 0.03 ml of 20% acetic acid (v/v) was injected into the submucosal layer at the junction of the fundus and an trum, about 1 cm proximal to the pylorus. Postoperative ly, the rats were maintained on rat chow and allowed free access to water (13) . Test compounds (TY-11345: 3, 10 and 30 mg/kg; omeprazole: 30 mg/kg) or vehicle were ad ministered orally from the first day after the operation for 14 consecutive days, once daily, to the rats with gastric ul cers. The rats were sacrificed at 24 hr after the final ad ministration of drugs, and their stomachs were examined for ulcers.
Ulcer or lesion index
The length (mm) of each lesion induced by water-im mersion stress, indomethacin or ethanol was measured macroscopically and summed per stomach, and used as the lesion index. The areas (mm2) of the mepirizole-in duced duodenal ulcers and acetic acid-induced ulcers were also measured and summed per stomach, and used as the ulcer index.
Statistics
Data are expressed as the mean ±S.E. A Williams multi ple comparison test was employed to determine the statistical significance of the data at the level of P < 0.05. ED50 values (the doses that inhibit gastric acid output and prevent the formation of the gastric and duodenal lesions by 50%) were calculated by the probit method.
RESULTS
Effects on the activity of H+/K+-ATPase in rabbit gastric mucosal microsomes The H+/K+-ATPase activity in the control group was 38.9±1.2 jcmol Pi/hr/mg protein (n=5). TY-11345 po tently inhibited the H+/K+-ATPase activity of purified rabbit gastric mucosal microsomes in a concentration-de pendent manner. The IC50 values (concentrations that in hibit the enzyme activity by 50%) were 5.8 , €M and 9.9 pM at pH 6.0 and pH 7.4, respectively. Omeprazole also inhibited H+/K+-ATPase activity, and the IC50 values were 16.1 pM and 201.9 pM at pH 6.0 and 7.4, respective ly. The effects of TY-11345 were about 3 and 20 times more potent than that of omeprazole (Fig. 2) . The inhibi tory effects of TY-1 1345 and omeprazole depended on the preincubation time. Nearly peak effects of TY-11345 and omeprazole were attained at 10 min and 30 min, respec tively. However, for the 30 min preincubation, the inhibi tory effects of TY-11345 and omeprazole at concentra tions of 10 pM and 30 pM, respectively, were almost equal at these concentrations and the values were about 85010 (Fig. 3) . Effects on gastric acid secretion Tetragastrin-stimulated secretion (Ghosh & Schild rats): The antisecretory activity of TY-11345 was evaluat ed by screening against tetragastrin-stimulated acid secre tion in rats and by comparing the results with those ob tained with omeprazole. Basal secretion in acute fistula rats was almost negligible, the acid output being 1.83 ± 0.02 pEq/ 10 min (n=5). Within 1.5 hr after the beginning of tetragastrin infusion, the acid secretion attained a fairly stable plateau, the acid output being 10.51 --'-1.20 pEq/10 min. Intravenous administration of TY-11345 at 0.3 to 1.0 mg/kg potently suppressed tetragastrin-stimulated gastric acid secretion for at least 180 min. The ED50 value of TY-11345 in the periods be tween 30 to 60 min was 0.39 mg/kg, so the effect of TY 11345 was approximately as potent as that of omeprazole. The ED50 value of TY-11345 in the periods between 150 to 180 min was 0.22 mg/kg, so the effect of TY-11345 was approximately twice as potent as that of omeprazole (Fig. 4) . Fig. 5 . Inhibitory effects of TY-11345 and omeprazole on gastric acid secretion in pylorus-ligated rats. The test compounds were administered intravenously immediately after pylorus ligation. Five hours after ligation, the gastric contents were collected and analyzed for volume, acid concentration and acid output. Each column represents the mean±S.E. for 8 rats. Statistically significant differences from the values for the control (vehicle) are indicated by * (P<0.05). Basal secretion (pylorus ligated rats): Ligation of the pylorus for 5 hr produced an accumulation of gastric juice; the volume, acidity and acid output were 4.65 ±0.29 ml/stomach, 94.5±2.5 mEq/1 and 0.457±0.039 mEq/5 hr (n=34), respectively. TY-11345, given intra venously at 0.1, 0.3 and 1.0 mg/kg immediately after the ligation, dose-dependently inhibited the gastric secre tion (volume, acid concentration and acid output). Omeprazole, given intravenously at 1, 3 and 10 mg/kg, also dose-dependently inhibited the volume, acid concen tration and acid output. The effect of TY-11345 was more potent than that of omeprazole (Fig. 5) . TY-11345, given intraduodenally at 1, 3 and 10 mg/kg immediately after the ligation, dose-dependently inhibited the gastric secre tion. The inhibition of acid output was complete when TY-11345 was administered in the dose of 10 mg/kg. Omeprazole also dose-dependently inhibited the volume, acid concentration and acid output. However, the degree of inhibition by omeprazole was weaker compared to that of TY 11345. The ED50 values of TY-11345 and omepra zole were 1.2 mg/kg and 10.2 mg/kg, respectively. The effect of TY-11345 was 9 times more potent than that of omeprazole (Fig. 6) . TY-11345 and omeprazole, ad ministered orally, also inhibited the gastric secretion. The potencies of both compounds were reduced in compari son to those of the respective compounds by intraduo denal administration. The ED50 values of TY-11345 and omeprazole were 4.0 mg/kg and 20.2 mg/kg, respectively (Fig. 7) . When each compound was administered orally at 19 hr before the ligation, TY-11345 and omeprazole still showed a significant reduction of the acid output. The ED50 values of TY-11345 and omeprazole were 12.7 mg/kg and 41.1 mg/kg, respectively (Fig. 8) .
Effects on acute experimental lesions
Water-immersion stress-induced gastric lesions: Water immersion stress for 6 hr produced several linear and dotted lesions in the glandular stomach, the mean lesion index in the vehicle-administered rats was 17.9±2.4 mm (n=13). TY-11345, administered orally at 0.3, 1 and 3 mg/kg, dose-dependently inhibited these lesions; the inhibitory percentage of the lesion index at each dose was 31%, 37010 and 84010, respectively. The ED50 value of TY-11345 was 0.92 mg/kg. Omeprazole also significantly inhibited the lesions. The ED50 value of omeprazole was 7.12 mg/kg. The effect of TY-11345 was 8 times more potent than that of omeprazole ( Table 1) . Indomethacin-induced gastric lesions: Indomethacin produced multiple lesions in the glandular stomach 6 hr after the treatment; the mean lesion index in the vehicle administered rats was 10.5±1.1 mm (n=9). TY-11345, administered orally at 0.3, 1 and 3 mg/kg, dose-depend ently inhibited the development of these lesions; the inhibitory percentage of the lesion index at each dose was 36070, 52% and 87010, respectively. The ED50 value of TY 11345 was 0.64 mg/kg. Omeprazole also dose-dependent ly inhibited the lesions. The ED50 value of omeprazole was 9.72 mg/kg. The effect of TY-1 1345 was 15 times more potent than that of omeprazole (Table 1) . Ethanol-induced gastric lesions: Ethanol produced hemorrhagic band-like lesions in the glandular stomach 1 hr after the treatment; the mean lesion index in the vehi cle-administered rats was 80.5 --±:6.4 mm (n = 15). TY 11345, administered orally at 3, 10 and 30 mg/kg, dose-de pendently inhibited the development of these lesions; the inhibitory percentage of the lesion index at each dose was 10%, 46% and 88%, respectively. The ED50 value of TY 11345 was 10.5 mg/kg. Omeprazole also dose-dependent ly inhibited the lesions. The ED50 value of omeprazole was 12.5 mg/kg. The effect of TY-11345 was similar to that of omeprazole (Table 1) .
Mepirizole-induced duodenal ulcers: Mepirizole produced one or two penetrating ulcers in the proximal duodenum, the mean ulcer index in the vehicle-admin istered rats was 14.8 ± 2.5 mm2 (n = 9). TY-11345, admin istered orally twice at 0.3, 1.0 and 3.0 mg/kg, dose-de pendently inhibited the development of these ulcers, the inhibitory percentage of the ulcer index at each dose was 8%, 64% and 87010, respectively. The ED50 value of TY 11345 was 0.90 mg/kg. Omeprazole also dose-dependent ly inhibited the ulcers. The ED50 value of omeprazole was 2.84 mg/kg. The effect of TY-1 1345 was 3 times more po tent than that of omeprazole (Table 1) .
Effect on chronic experimental ulcers Acetic acid-induced gastric ulcers: The submucosal injection of acetic acid solution produced visible and con sistent ulcers in the stomach; the mean ulcer index in the vehicle-administered rats was 6.76± 1.14 mm2 (n=12). Oral administration of TY-11345, at 10 and 30 mg/kg once daily, for 14 days, dose-dependently accelerated the healing of the ulcers, the inhibitory percentage of the ulcer index at each dose was 52010 and 82010, respectively. The ED50 value of TY-11345 was 16.5 mg/kg/day. However, omeprazole tended to accelerate the healing at the dose of 30 mg/kg once a daily, for 14 ,days. The healing effect of TY-11345 was superior to that of omeprazole (Table 1) .
DISCUSSION
The newly synthesized proton pump inhibitor TY 11345 exhibited a potent antisecretory effect, and it mark edly prevented the gastric and duodenal mucosal lesions and accelerated the healing of acetic acid ulcers in various experimental animals.
Previous reports have shown that the proton pump inhi bitors, such as omeprazole, exist predominantly in their neutral base form at physiological pH, and they show their inhibitory effect when transformed into the active form sulfenamide, which modifies the SH group of H+/ K+-ATPase under acid conditions in the parietal cells (4, 14) . In the in vitro study, TY-11345 potently inhibited H+ /K+-ATPase activity in isolated rabbit gastric mucosal microsomes in acidic solution (pH 6.0). At pH 6.0, the IC50 values of TY-11345 and omeprazole were 5.8 pM and 16.1 pM, respectively. Our results for omeprazole confirmed the findings of Wallmark et al. (15) , who found that the activity of omeprazole is pH-dependent; the efficacy of omeprazole was potent when the pH of the medium was 6.0, but it became weak at pH 7.4. TY-11345 also showed a pH-dependent response; the effect of TY 11345 was about 3 times more potent compared with that of omeprazole at pH 6.0. In addition, the nearly peak effect of TY-1 1345 was attained more rapidly than that of omeprazole, when compared with the time course of H+ /K+-ATPase inhibition. Furthermore, from nuclear mag netic resonance studies, we have data confirming the trans formation of TY-11345 into the sulfenamide form under the acidic condition (data not shown). From these data, we can deduce that TY-1 1345 is likely to be transformed into the SH-reactive form, because it contains a cyclohep tenopyridine ring as a fundamental structural element.
In the in vivo study, TY-11345 significantly suppressed both the basal and stimulated acid secretion. In Ghosh & Schild rats, the effect of TY-1 1345 for tetragastrin stimu lated acid secretion was twice or 3 times more potent than that of omeprazole when they were administered intra venously. These results indicated that the potent anti secretory effect of TY-11345 was correlated with the inhi bition of H+/K+-ATPase; the inhibitory effect of TY 11345 on H+/K+-ATPase was also 3 times more potent in vitro compared to that of omeprazole. In pylorus ligated rats, TY-11345 also showed the antisecretory effect, and the effect by intravenous, intraduodenal or oral routes was 4 to 9 times more potent than that of omeprazole. Thus, TY-11345 showed the potent antisecretory effect by the various routes. When compared with intraduodenal administration, the oral potency of TY-11345 was 3 times lower in pylorus ligated rats. Larsson et al. reported that the antisecretory effect of omeprazole administered orally was attenuated compared with that administered intraduo denally (16) . Since TY-11345 is unstable at acidic pH, partial degradation may have occurred in the stomach, before absorption, thereby resulting in a lower systemic bioavailability and effectiveness by the oral route. On the other hand, it should be noted that TY-1 1345 persistently suppressed gastric acid secretion 24 hr after the adminis tration in pylorus ligated rats. This long and potential antisecretory effect would be a beneficial property for the clinical use of this drug for diseases with acid-induced damage.
As expected from its potent antisecretory effect, TY 11345 had a potent inhibitory effect on various types of acutely-induced gastric lesions; i.e., water-immersion stress-, indomethacin-induced gastric lesions. TY-11345 also prevented mepirizole-induced duodenal ulcers, which are presumed to be induced by the inflow of ac cumulated gastric juice into the proximal duodenum and attenuate defensive mechanism. These lesions are also prevented by histamine-H2-blocking agents (17, 18) . These findings suggest that the pathogenesis of these le sions is related to gastric acid secretion. The anti-lesion effects of TY-11345 were 3 15 times more potent than that of omeprazole. We observed that the ED50 values of TY-11345 on these experimental lesions were consider ably lower than that on acid output in pylorus ligated rats. Therefore, TY-11345 seems to prevent lesion formation mainly by a potent and long-acting antisecretory activity and partly by unknown mechanisms. Yamamoto et al. (17) reported that orally administered omeprazole sig nificantly prevented experimental gastric mucosal lesions, but the low dose which inhibited gastric lesions was less effective on basal acid secretion. They indicated that omeprazole had a mucosal protective effect unrelated to the reduction of acid secretion.
TY-11345 administered orally also prevented mucosal lesions caused by absolute ethanol. This lesion model is often used to determine the cytoprotective property of drugs, as these lesions are not prevented by antisecretory agents but by low doses of prostaglandins (11) . Omepr azole is also known to have a cytoprotective action (19, 20) . We also confirmed the cytoprotective action of omeprazole.
It is considered that the cytoprotective mechanism of omeprazole is the maintenance of gastric mucosal blood flow (21), mucus secretion (22) or mucosal oxygenation (23) ; however the accurate mechanism remains unknown, except that it is unrelated to the biosyn thesis of mucosal prostaglandins or gastric acid inhibition (19, 24) .
TY-11345 at 30 mg/kg significantly accelerated the spontaneous healing of chronic gastric ulcers induced by acetic acid, and omeprazole tended to accelerate the heal ing of ulcers at the same dose as TY-11345. Yamamoto et al. reported that omeprazole at 100 mg/kg twice a day accelerated the healing of ulcers (17) .
These results taken together suggest that the new pro ton pump inhibitor TY-1 1345 has an excellent curative and preventive effect on gastric and duodenal ulcers, mainly by suppressing acid secretion through inhibition of H+/ K+-ATPase and partly by protecting the gastroduodenal mucosa, and will be a beneficial use for the treatment of human peptic ulcers and diseases with acid-induced damage.
